Channel News AsiaCelladon says heart treatment fails in trialReutersNEW YORK (Reuters) - Celladon Corp said its heart failure gene therapy Mydicar failed to meet its primary and secondary endpoints in an important trial. "We are surprised and very disappointed that Mydicar failed to meet the endpoints in the CUPID2 trial, ...Celladon's gene therapy for heart failure bombs in PhIIbFierceBiotechCelladon Reports Negative Results for CUPID2 Trial of MYDICAR(R) in ...CNNMoneyall 4 news articles »
